Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03404206 · ClinicalTrials.gov registry record · Phase 4

A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain

A Phase 4 study, sponsored by Bayer.

Completed
Registry status
Phase 4
Development phase
387
Enrollment target

NCT03404206: Completed Phase 4 study, sponsored by Bayer.

NCT03404206 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 387 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03404206, a Phase 4 study, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 4
Development phase
387 participants
Enrollment target

Study Summary

To compare the duration of analgesic efficacy as determined by the time to rescue medication of a single oral dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo over 24 hours in subjects experiencing moderate to severe post-impaction surgery dental pain. To compare the overall analgesic effect (SPID 0-24) of a single dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo. To compare the overall relief from pain (TOTPAR 0-24) of a single dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo.

Primary Outcome

Time to first use of rescue medication was estimated using Kaplan-Meier method. If a subject did not take the rescue medication during the treatment period, (s)he was censored at the time of last assessment.

Interventions

  • DRUG Placebo
  • DRUG Naproxen Sodium (Aleve, BAY117031)
  • DRUG Ibuprofen (Advil)

Trial Details

FieldValue
Enrollment Target 387 participants
Start Date 2018-02-12
Est. Completion 2018-07-10
Phase Phase 4
Bayer

591 total trials

What the finished NCT03404206 record still lists

NCT03404206 is an interventional study that assigns participants to a tested intervention. The registered 387 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (25% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT03404206 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03404206 about?

NCT03404206 is a clinical study titled "A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain". To compare the duration of analgesic efficacy as determined by the time to rescue medication of a single oral dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo over 24 hours in subjects experiencing moderate to severe post-impaction sur...

What is the current status of trial NCT03404206?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 387 participants. The study started on 2018-02-12. Estimated completion is 2018-07-10.

What interventions are being tested in trial NCT03404206?

The interventions under investigation include: Placebo (DRUG), Naproxen Sodium (Aleve, BAY117031) (DRUG), Ibuprofen (Advil) (DRUG).

Who is sponsoring clinical trial NCT03404206?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03404206's enrollment target sits among peer trials

387 222nd of 2000 higher than 1,779 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03761108 · 387 participants · Phase 1

    Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

  • NCT05572632 · 387 participants · NA

    Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD

  • NCT06917079 · 387 participants · Phase 1

    BBO-11818 in Adult Subjects With KRAS Mutant Cancer

  • NCT04092010 · 388 participants · NA

    Improving Preschool Outcomes by Addressing Maternal Depression in Head Start

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03404206, the US trial registry maintained by the National Library of Medicine. NCT03404206 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.